Quick Answer
EVO ICL is designed as a permanent implant with no scheduled replacement timeline. Clinical studies following patients for up to 15 years show stable lens position, stable intraocular pressure, and maintained visual outcomes in the vast majority of cases. The Collamer material does not degrade over time. Most patients who receive EVO ICL can expect it to remain in place for decades — potentially for life — though certain life events such as cataract development may eventually require its removal.
Detailed Explanation
Unlike soft contact lenses that must be replaced regularly, or glasses with lenses that scratch and age, the EVO ICL is engineered as a long-duration implant. The lens material — Collamer — is a collagen copolymer that is biocompatible, UV-absorbing, and biologically stable within the ocular environment.
What the long-term data shows:
The most comprehensive long-term studies of implantable collamer lenses — including ICL and its predecessor models — follow patients out to 10, 12, and in some studies, 15 years. Key findings from this body of evidence include:
- Lens stability: Minimal lens migration or decentration in properly sized implants. The posterior chamber location is mechanically stable, and the lens is not subject to gravitational displacement in normal daily activity.
- Intraocular pressure: No clinically significant trend toward elevated IOP in appropriately screened and sized patients over long follow-up periods. The EVO design’s KS-AquaPORT specifically improved aqueous flow compared to older models, reducing the IOP elevation risk that was a concern in earlier ICL generations.
- Endothelial cell density: The corneal endothelium — the cell layer responsible for maintaining corneal clarity — is monitored in long-term ICL studies. Data shows minimal endothelial cell loss in properly placed EVO ICL beyond what would be expected with normal aging.
- Visual acuity: Stable uncorrected visual acuity maintained over follow-up periods of 10 or more years in the majority of patients. Prescription changes, when they occur, are attributable to natural refractive shifts rather than lens degradation.
The natural aging variable:
EVO ICL is permanent in the sense that the lens material does not wear out. However, the eye continues to change over a patient’s lifetime:
- Presbyopia: Around age 45 to 50, the natural crystalline lens loses flexibility and near vision becomes difficult. EVO ICL does not prevent presbyopia; patients corrected for distance vision will still need reading glasses as they age.
- Cataract formation: By age 65 to 75, most people develop some degree of natural lens opacity (cataract). When a cataract matures to the point of requiring surgical removal, the EVO ICL may need to be explanted as part of the cataract surgery approach. In some cases it can be retained, depending on the surgical technique used.
- Prescription progression: A small percentage of patients — particularly those whose myopia had not fully stabilized at the time of surgery — may experience meaningful prescription change over the years following EVO ICL. In these cases, lens exchange for a different power, or supplemental laser treatment, may be recommended.
For surgeons with recognized expertise in EVO ICL long-term management, visit the EVO ICL Awards page.
The role of annual monitoring:
Even though EVO ICL is permanent and generally trouble-free, annual comprehensive eye examinations are strongly recommended throughout the patient’s life after implantation. These exams allow the treating physician to monitor:
- Intraocular pressure trends
- Lens vault (the clearance between the ICL and the natural lens)
- Endothelial cell density (typically checked at 1 month, 1 year, and then every 2 to 5 years)
- Any signs of cataract formation
- Overall refractive stability
Annual monitoring is not optional — it is part of the responsible long-term stewardship of an intraocular implant.
Important Considerations
Patients sometimes interpret “permanent” as meaning “zero follow-up required.” This is incorrect. The permanence of EVO ICL refers to the lens material’s longevity — not to the elimination of ongoing ophthalmic care.
Another common misconception is that EVO ICL prevents or delays cataract. It does not. Older ICL designs (pre-EVO) had a documented association with accelerated anterior subcapsular cataract formation, which occurred when the lens vaulted too low and made contact with the natural lens. The EVO design’s improved KS-AquaPORT system substantially reduces this risk, but it does not eliminate the natural aging process that causes cataracts.
Patients should also understand that lens longevity is highly dependent on correct sizing at the time of implantation. A correctly sized EVO ICL — with appropriate vault over the natural lens — is the single most important technical factor in achieving stable, long-term outcomes. This is one reason to prioritize surgeons with high case volume and rigorous preoperative sizing protocols.
What to Do Next
Ask your prospective surgeon specifically about their long-term monitoring protocol. A practice that performs EVO ICL without a structured follow-up program is not providing comprehensive care.
Before your consultation, review What Is EVO ICL Surgery? to fully understand the procedure itself, and What Are the Risks of EVO ICL Surgery? to understand what long-term monitoring is designed to detect.
Related Questions
What if my prescription changes years after surgery? See What Happens If My Vision Changes After EVO ICL? for options when long-term refractive shifts occur.
Can the lens be taken out if needed? Yes — read Can EVO ICL Be Removed? to understand the removal process and when it becomes clinically indicated.
What are the risks over the long term? Review What Are the Risks of EVO ICL Surgery? for a complete assessment of short- and long-term complication risks.